These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30287613)

  • 1. Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study.
    Davies Forsman L; Niward K; Hu Y; Zheng R; Zheng X; Ke R; Cai W; Hong C; Li Y; Gao Y; Werngren J; Paues J; Kuhlin J; Simonsson USH; Eliasson E; Alffenaar JW; Mansjö M; Hoffner S; Xu B; Schön T; Bruchfeld J
    BMJ Open; 2018 Oct; 8(9):e023899. PubMed ID: 30287613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
    Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
    Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.
    Xia H; Zheng Y; Liu D; Wang S; He W; Zhao B; Song Y; Ou X; Zhou Y; van den Hof S; Cobelens F; Zhao Y
    Microbiol Spectr; 2021 Dec; 9(3):e0040921. PubMed ID: 34851179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP).
    Ekqvist D; Bornefall A; Augustinsson D; Sönnerbrandt M; Nordvall MJ; Fredrikson M; Carlsson B; Sandstedt M; Simonsson USH; Alffenaar JC; Paues J; Niward K
    BMJ Open; 2022 Mar; 12(3):e054788. PubMed ID: 35273049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.
    Forsman LD; Jonsson J; Wagrell C; Werngren J; Mansjö M; Wijkander M; Groenheit R; Hammar U; Giske CG; Schön T; Bruchfeld J
    Clin Infect Dis; 2019 Sep; 69(8):1394-1402. PubMed ID: 30561569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Using of the Sensititre MycoTB Plate Method for the Detection of Anti-tuberculous Drug Susceptibility of Rifampin Resistant Mycobacterium tuberculosis Complex Isolates].
    Ceyhan İ; Vezir S
    Mikrobiyol Bul; 2020 Apr; 54(2):211-222. PubMed ID: 32723277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study.
    Heysell SK; Mpagama SG; Ogarkov OB; Conaway M; Ahmed S; Zhdanova S; Pholwat S; Alshaer MH; Chongolo AM; Mujaga B; Sariko M; Saba S; Rahman SMM; Uddin MKM; Suzdalnitsky A; Moiseeva E; Zorkaltseva E; Koshcheyev M; Vitko S; Mmbaga BT; Kibiki GS; Pasipanodya JG; Peloquin CA; Banu S; Houpt ER
    Clin Infect Dis; 2023 Feb; 76(3):497-505. PubMed ID: 35731948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.
    Zheng X; Zheng R; Hu Y; Werngren J; Forsman LD; Mansjö M; Xu B; Hoffner S
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4786-92. PubMed ID: 27246779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study.
    van den Elsen SH; Sturkenboom MG; Akkerman O; Barkane L; Bruchfeld J; Eather G; Heysell SK; Hurevich H; Kuksa L; Kunst H; Kuhlin J; Manika K; Moschos C; Mpagama SG; Muñoz Torrico M; Skrahina A; Sotgiu G; Tadolini M; Tiberi S; Volpato F; van der Werf TS; Wilson MR; Zúñiga J; Touw DJ; Migliori GB; Alffenaar JW
    BMJ Open; 2020 Jun; 10(6):e035350. PubMed ID: 32554740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring in the treatment of tuberculosis: an update.
    Alsultan A; Peloquin CA
    Drugs; 2014 Jun; 74(8):839-54. PubMed ID: 24846578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania.
    Mpagama SG; Houpt ER; Stroup S; Kumburu H; Gratz J; Kibiki GS; Heysell SK
    BMC Infect Dis; 2013 Sep; 13():432. PubMed ID: 24034230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Serial Multidrug-Resistant Tuberculosis Strains Causing Treatment Failure and Within-Host Evolution by Whole-Genome Sequencing.
    Chen X; He G; Lin S; Wang S; Sun F; Chen J; Zhang W
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33361124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma drug activity assay for treatment optimization in tuberculosis patients.
    Heysell SK; Mtabho C; Mpagama S; Mwaigwisya S; Pholwat S; Ndusilo N; Gratz J; Aarnoutse RE; Kibiki GS; Houpt ER
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5819-25. PubMed ID: 21968363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB.
    Lee SH; Seo KA; Lee YM; Lee HK; Kim JH; Shin C; Ghim JR; Shin JG; Kim DH
    Yonsei Med J; 2015 Jul; 56(4):961-7. PubMed ID: 26069117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.
    Velayati AA; Masjedi MR; Farnia P; Tabarsi P; Ghanavi J; ZiaZarifi AH; Hoffner SE
    Chest; 2009 Aug; 136(2):420-425. PubMed ID: 19349380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Beijing, China.
    Yu X; Zeng X; Shi W; Hu Y; Nie W; Chu N; Huang H
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China.
    Liu Y; Gao M; Du J; Wang L; Gao J; Shu W; Wang Y; Xue Z; Li L; Pang Y
    Clin Infect Dis; 2021 Nov; 73(9):e3391-e3397. PubMed ID: 32667984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.
    Vu DH; Bolhuis MS; Koster RA; Greijdanus B; de Lange WC; van Altena R; Brouwers JR; Uges DR; Alffenaar JW
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5758-63. PubMed ID: 22926568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.